

# Brett G M Hughes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3262727/publications.pdf>

Version: 2024-02-01

148  
papers

7,690  
citations

145106

33  
h-index

66518

82  
g-index

149  
all docs

149  
docs citations

149  
times ranked

10838  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatment. <i>British Journal of Nutrition</i> , 2023, 129, 406-415.	1.2	7
2	A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 776-787.	1.8	33
3	CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 434-445.	0.5	21
4	Evaluation of a novel pre-treatment model of nutrition care for patients with head and neck cancer receiving chemoradiotherapy. <i>Nutrition and Dietetics</i> , 2022, 79, 206-216.	0.9	6
5	Protocol of DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural Mesothelioma—a phase 3 randomised trial. <i>BMJ Open</i> , 2022, 12, e057663.	0.8	9
6	Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. <i>Journal of Clinical Oncology</i> , 2022, 40, 2321-2332.	0.8	79
7	Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. <i>Oral Oncology</i> , 2022, 128, 105815.	0.8	17
8	A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 515-524.	2.4	9
9	The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic review. <i>Supportive Care in Cancer</i> , 2022, 30, 7191-7204.	1.0	2
10	Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
11	Understanding the tumor microenvironment in head and neck squamous cell carcinoma. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	10
12	Efficacy of programmed cell death protein 1 (PD1) inhibitors in cutaneous squamous cell carcinoma (cSCC) patients with large nerve-perineural invasion (LN-PNI): A multicenter retrospective study. <i>Journal of Clinical Oncology</i> , 2022, 40, e21577-e21577.	0.8	0
13	DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—a phase 3 randomized trial. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8599-TPS8599.	0.8	0
14	Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE). <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e109-e116.	0.7	6
15	Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes*. <i>British Journal of Dermatology</i> , 2021, 184, 1113-1122.	1.4	7
16	A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and Immunotherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma. <i>Radiation Oncology</i> , 2021, 16, 69.	1.2	12
17	KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC). <i>Journal of Clinical Oncology</i> , 2021, 39, 9546-9546.	0.8	0
18	Randomized trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01): A Trans-Tasman Radiation Oncology Group study. <i>Journal of Clinical Oncology</i> , 2021, 39, 6012-6012.	0.8	6

#	ARTICLE	IF	CITATIONS
19	DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesotheliomaâ€”A phase 3 randomized trial.. Journal of Clinical Oncology, 2021, 39, TPS8586-TPS8586.	0.8	5
20	EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Nonâ€”Small Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, e859-e869.	1.1	23
21	Semiquantitative research protocol to explore cancer care workforce perceptions of the health system response to COVID-19 preparations in Southeast Queensland, Australia. BMJ Open, 2021, 11, e044655.	0.8	2
22	Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?. , 2021, 9, e002248.		35
23	Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) â€” A Trans-Tasman Radiation Oncology Group Study. International Journal of Radiation Oncology Biology Physics, 2021, 111, 876-886.	0.4	68
24	Abstract CT006: Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629. Cancer Research, 2021, 81, CT006-CT006.	0.4	2
25	Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. , 2021, 9, e002757.		46
26	Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629. Dermatology and Therapy, 2021, 11, 1777-1790.	1.4	8
27	Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Annals of Oncology, 2021, 32, 1276-1285.	0.6	82
28	The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC). Lung Cancer, 2021, 160, 73-77.	0.9	6
29	701â€”Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC). , 2021, 9, A729-A729.		2
30	Weighted activity unit effect: evaluating the cost of diagnosisâ€”related group coding. Internal Medicine Journal, 2020, 50, 440-444.	0.5	7
31	Evaluation of a speech pathology service delivery model for patients at low dysphagia risk during radiotherapy for HNC. Supportive Care in Cancer, 2020, 28, 1867-1876.	1.0	3
32	Prior or concurrent radiotherapy and nivolumab immunotherapy in nonâ€”small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 56-62.	0.7	10
33	Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discovery, 2020, 10, 40-53.	7.7	219
34	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ Tâ€”Cells. Immunity, 2020, 53, 805-823.e15.	6.6	79
35	Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). Journal of Clinical Oncology, 2020, 38, 2916-2925.	0.8	170
36	Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinoma. Cancer Science, 2020, 111, 3854-3861.	1.7	31

#	ARTICLE	IF	CITATIONS
37	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. <i>Lancet Oncology</i> , The, 2020, 21, 1213-1223.	5.1	109
38	915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). <i>Annals of Oncology</i> , 2020, 31, S660-S661.	0.6	9
39	Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. <i>Future Oncology</i> , 2020, 16, 1235-1243.	1.1	36
40	Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. , 2020, 8, e000775.		113
41	A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 142, 34-40.	0.9	27
42	An Occult HPV-Driven Oropharyngeal Squamous Cell Carcinoma Discovered Through a Saliva Test. <i>Frontiers in Oncology</i> , 2020, 10, 408.	1.3	23
43	Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 607349.	1.3	22
44	Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10018-10018.	0.8	34
45	KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 6505-6505.	0.8	21
46	Adenosine receptor blockade with ciferadenant +/- atezolizumab in advanced metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 129-129.	0.8	21
47	Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6530-6530.	0.8	4
48	Abstract 3384: Characterization of the tumor microenvironment and liquid biopsy in head and neck and non-small cell lung cancer. , 2020, , .		1
49	Outcomes of incidental pulmonary nodules in head-and-neck squamous cell cancer patients treated with curative intent. <i>Journal of Head &amp; Neck Physicians and Surgeons</i> , 2020, 8, 17.	0.2	0
50	Psychosocial impacts of COVID-19 on oncology workforces: Metro versus regional Australia.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1111-1111.	0.8	1
51	Emotional impact of COVID-19 preparations on metro and regional cancer workforces in Queensland Australia: "We are all in this together".. <i>Journal of Clinical Oncology</i> , 2020, 38, 44-44.	0.8	0
52	Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns. <i>Supportive Care in Cancer</i> , 2019, 27, 573-581.	1.0	5
53	CXCR4 and PD-1 Expression in Head and Neck Cancer with Perineural Spread. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2019, 80, 018-022.	0.4	4
54	Traveling With Cancer: A Guide for Oncologists in the Modern World. <i>Journal of Global Oncology</i> , 2019, 5, 1-10.	0.5	3

#	ARTICLE	IF	CITATIONS
55	An update: circulating tumor cells in head and neck cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1109-1115.	1.5	21
56	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 1915-1928.	6.3	1,804
57	Patterns of care for stage III non-small cell lung cancer in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 93-100.	0.7	5
58	The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancer. <i>Supportive Care in Cancer</i> , 2019, 27, 4627-4637.	1.0	19
59	EGFR mutations in lung cancer: not all equal in the eyes of the immune system?. <i>Annals of Translational Medicine</i> , 2019, 7, S326-S326.	0.7	0
60	Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). <i>Trials</i> , 2019, 20, 753.	0.7	20
61	Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib. <i>BMJ Case Reports</i> , 2019, 12, e232868.	0.2	5
62	Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6000-6000.	0.8	118
63	Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6081-6081.	0.8	6
64	Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9526-9526.	0.8	27
65	KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9598-TPS9598.	0.8	5
66	Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS129-TPS129.	0.8	0
67	Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FDG-PET staging.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20045-e20045.	0.8	0
68	Abstract CT170: KEYNOTE-629: Phase II study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma. , 2019, , .		0
69	Comparison of Nutritional and Clinical Outcomes in Patients with Head and Neck Cancer Undergoing Chemoradiotherapy Utilizing Prophylactic versus Reactive Nutrition Support Approaches. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2018, 118, 627-636.	0.4	40
70	Clinical guidance for radioiodine refractory differentiated thyroid cancer. <i>Clinical Endocrinology</i> , 2018, 88, 529-537.	1.2	27
71	Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. <i>Targeted Oncology</i> , 2018, 13, 89-98.	1.7	63
72	Identifying barriers to physical activity in patients with lung cancer: An Australian pilot study. <i>Annals of Oncology</i> , 2018, 29, viii756.	0.6	0

#	ARTICLE	IF	CITATIONS
73	P2.01-50 Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, S684.	0.5	1
74	OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result. Journal of Thoracic Oncology, 2018, 13, S338-S339.	0.5	39
75	P1.01-52 BR-34- Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Chemotherapy in Patients with Metastatic Squamous or Non-Squamous NSCLC. Journal of Thoracic Oncology, 2018, 13, S480-S481.	0.5	3
76	Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 1784-1791.	0.5	75
77	Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: A prospective investigation of acute swallowing and toxicity patterns. Head and Neck, 2018, 40, 1955-1966.	0.9	13
78	PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. New England Journal of Medicine, 2018, 379, 341-351.	13.9	997
79	Abstract A084: DENALI: a 3-arm double-blind randomized phase 2 study of carboplatin, pemetrexed, and placebo (CPP) versus carboplatin, pemetrexed, and either 1 or 2 truncated courses of demcizumab (CPD) in patients with non-squamous non-small cell lung cancer (NSCLC). Molecular Cancer Therapeutics, 2018, 17, A084-A084.	1.9	3
80	DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results.. Journal of Clinical Oncology, 2018, 36, 8503-8503.	0.8	22
81	Avelumab (anti-PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.. Journal of Clinical Oncology, 2018, 36, 9008-9008.	0.8	47
82	Immune-related adverse events and nivolumab outcomes in non-small cell lung cancer patients: A multi-institutional, retrospective cohort study.. Journal of Clinical Oncology, 2018, 36, 9067-9067.	0.8	7
83	Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC).. Journal of Clinical Oncology, 2018, 36, 9519-9519.	0.8	2
84	CXCR4 and PD-1 Expression in Head and Neck Cancer with Perineural Spread. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, S1-S188.	0.4	0
85	Hospital admissions due to immuno-oncology therapy associated toxicity: A retrospective analysis at two tertiary oncology centres.. Journal of Clinical Oncology, 2018, 36, e18805-e18805.	0.8	0
86	Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2018, 36, 8568-8568.	0.8	0
87	Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study.. Journal of Clinical Oncology, 2018, 36, 8566-8566.	0.8	0
88	An analysis of incidental and symptomatic pulmonary embolism (PE) in medical oncology patients. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 243-248.	0.7	5
89	Investigation of p16 status, chemotherapy regimen, and other nutrition markers for predicting gastrostomy in patients with head and neck cancer. Head and Neck, 2017, 39, 868-875.	0.9	8
90	Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 137-144.	0.7	5

#	ARTICLE	IF	CITATIONS
91	Randomised controlled trial of early prophylactic feeding vs standard care in patients with head and neck cancer. <i>British Journal of Cancer</i> , 2017, 117, 15-24.	2.9	55
92	Patterns of dysphagia and acute toxicities in patients with head and neck cancer undergoing helical IMRT±concurrent chemotherapy. <i>Oral Oncology</i> , 2017, 64, 1-8.	0.8	42
93	Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin. <i>Head and Neck</i> , 2017, 39, 679-683.	0.9	39
94	Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 277-288.	0.7	36
95	Impact of early prophylactic feeding on long term tube dependency outcomes in patients with head and neck cancer. <i>Oral Oncology</i> , 2017, 72, 17-25.	0.8	9
96	Tube feeding during treatment for head and neck cancer – Adherence and patient reported barriers. <i>Oral Oncology</i> , 2017, 72, 140-149.	0.8	23
97	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK -positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. <i>European Journal of Cancer</i> , 2017, 82, 27-33.	1.3	25
98	P2.07-032 Outcomes of Nivolumab in Metastatic NSCLC Patients via the Access Program Across Multiple Tertiary Oncology Centres. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2427-S2428.	0.5	1
99	Pembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM): Outcomes in real-life setting in Australia (AUS) and Switzerland (CH). <i>Annals of Oncology</i> , 2017, 28, xi8.	0.6	0
100	Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors. <i>Cancer Research</i> , 2017, 77, CT119-CT119.	0.4	26
101	Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients. <i>Journal of Clinical Oncology</i> , 2017, 35, 3004-3004.	0.8	37
102	Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). <i>Journal of Clinical Oncology</i> , 2017, 35, 8506-8506.	0.8	1
103	Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression. <i>Journal of Clinical Oncology</i> , 2017, 35, 8514-8514.	0.8	14
104	Improving guideline sensitivity and specificity for the identification of proactive gastrostomy placement in patients with head and neck cancer. <i>Head and Neck</i> , 2016, 38, E1163-71.	0.9	10
105	Validation of an updated evidence-based protocol for proactive gastrostomy tube insertion in patients with head and neck cancer. <i>European Journal of Clinical Nutrition</i> , 2016, 70, 574-581.	1.3	19
106	Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2016, 27, vi437.	0.6	6
107	Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, e222-e228.	0.7	8
108	Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 661-668.	0.8	548

#	ARTICLE	IF	CITATIONS
109	A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM), pemetrexed (PEM) & carboplatin (CARBO) in patients (pts) with 1 <sup>st</sup> line non-squamous NSCLC.. Journal of Clinical Oncology, 2016, 34, 9023-9023.	0.8	2
110	Oncologists' estimates of expected survival time and scenarios for survival: accuracy in the ALTG NITRO trial of 1st line chemotherapy for advanced non-small-cell lung cancer.. Journal of Clinical Oncology, 2016, 34, 9074-9074.	0.8	2
111	Lean thinking: Exploring the volume of overhead and supplementary tasks (OST) in cancer care (CC) in the oncology outpatient encounter (OOE) in two tertiary centres.. Journal of Clinical Oncology, 2016, 34, 6589-6589.	0.8	0
112	An unusual recurrence of adenosquamous carcinoma of the lung. Cancer Treatment Communications, 2015, 4, 37-40.	0.4	1
113	Swallowing outcomes and PEG dependence in head and neck cancer patients receiving definitive or adjuvant radiotherapy +/ chemotherapy with a proactive PEG: A prospective study with long term follow up. Oral Oncology, 2015, 51, 622-628.	0.8	20
114	Patients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile?. European Journal of Cancer, 2015, 51, 1529-1537.	1.3	23
115	A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial. Annals of Oncology, 2015, 26, 2280-2286.	0.6	28
116	New radiotherapy techniques do not reduce the need for nutrition intervention in patients with head and neck cancer. European Journal of Clinical Nutrition, 2015, 69, 1119-1124.	1.3	18
117	Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).. Journal of Clinical Oncology, 2015, 33, 8008-8008.	0.8	18
118	A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM), pemetrexed (PEM) & carboplatin (CARBO) in pts with 1 <sup>st</sup> line non-squamous NSCLC.. Journal of Clinical Oncology, 2015, 33, 8045-8045.	0.8	1
119	Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Translational Lung Cancer Research, 2015, 4, 36-54.	1.3	499
120	Pertuzumab and Erlotinib in Patients With Relapsed Non-Small Cell Lung Cancer: A Phase II Study Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging. Oncologist, 2014, 19, 175-176.	1.9	21
121	Protocol for a randomized controlled trial of early prophylactic feeding via gastrostomy versus standard care in high risk patients with head and neck cancer. BMC Nursing, 2014, 13, 17.	0.9	15
122	Nutrition outcomes following implementation of validated swallowing and nutrition guidelines for patients with head and neck cancer. Supportive Care in Cancer, 2014, 22, 2381-2391.	1.0	35
123	The ENHANCES study: Enhancing Head and Neck Cancer patients' Experiences of Survivorship: study protocol for a randomized controlled trial. Trials, 2014, 15, 191.	0.7	18
124	Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Annals of Oncology, 2014, 25, 2047-2052.	0.6	129
125	Myocardial infarction secondary to 5-fluorouracil: Not an absolute contraindication to rechallenge?. International Journal of Cardiology, 2014, 172, e331-e333.	0.8	26
126	A phase 1b study of the anticancer stem cell agent demcizumab (DEM), pemetrexed (PEM), and carboplatin (CARBO) in pts with first-line nonsquamous NSCLC.. Journal of Clinical Oncology, 2014, 32, 2544-2544.	0.8	1



#	ARTICLE	IF	CITATIONS
127	Validated swallowing and nutrition guidelines for patients with head and neck cancer: Identification of high-risk patients for proactive gastrostomy. <i>Head and Neck</i> , 2013, 35, 1385-1391.	0.9	36
128	Decreased hospital stay and significant cost savings after routine use of prophylactic gastrostomy for high-risk patients with head and neck cancer receiving chemoradiotherapy at a tertiary cancer institution. <i>Head and Neck</i> , 2013, 35, 436-442.	0.9	43
129	A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. <i>Lung Cancer</i> , 2013, 81, 422-427.	0.9	51
130	Comment on "The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer". <i>British Journal of Cancer</i> , 2013, 109, 526-528.	2.9	0
131	18F-fluoro-L-thymidine Positron Emission Tomography for Mucosal Head and Neck Squamous Cell Carcinoma Treated with Definitive Chemoradiation: A Pilot Study of Nodal Assessment and Tracer Safety. <i>ISRN Molecular Imaging</i> , 2013, 2013, 1-7.	0.0	1
132	Abstract A71: A Phase Ib study of demcizumab (DEM, anti-DLL4) plus pemetrexed and carboplatin in patients with first line stage IIIb/IV non-squamous non-small cell lung cancer.. , 2013, , .		1
133	Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S579-92.	0.6	37
134	Challenging the Distal-to-Proximal Cannulation Technique for Administration of Anticancer Therapies. <i>Cancer Nursing</i> , 2012, 35, E35-E40.	0.7	2
135	The relationship between vitamin D and chemotherapy-induced toxicity " a pilot study. <i>British Journal of Cancer</i> , 2012, 107, 158-160.	2.9	12
136	Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non-Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib. <i>Clinical Cancer Research</i> , 2012, 18, 2391-2401.	3.2	387
137	Quality-of-life among head and neck cancer survivors at one year after treatment " A systematic review. <i>European Journal of Cancer</i> , 2012, 48, 2391-2408.	1.3	121
138	A prospective study investigating the impact of definitive chemoradiation in locoregionally advanced squamous cell carcinoma of the skin.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8538-8538.	0.8	2
139	Phase II trial of BNC105P as second-line chemotherapy for advanced malignant pleural mesothelioma (MPM): Australasian Lung Cancer Trials Group and NHMRC Clinical Trials Centre Collaboration.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7079-7079.	0.8	0
140	Clinicopathological report: Bilateral choroidal metastases from papillary thyroid cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 11-14.	0.7	8
141	Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non-Small Cell Lung Cancer Treated with Erlotinib. <i>Clinical Cancer Research</i> , 2011, 17, 3304-3315.	3.2	126
142	Medical management of mesothelioma. <i>Australian Prescriber</i> , 2011, 34, 144-147.	0.5	2
143	Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. <i>Journal of Clinical Neuroscience</i> , 2010, 17, 970-974.	0.8	54
144	The segmental distribution and clinical significance of colorectal fluorodeoxyglucose uptake incidentally detected on PET-CT. <i>Nuclear Medicine Communications</i> , 2009, 30, 333-337.	0.5	50

#	ARTICLE	IF	CITATIONS
145	Docetaxel-induced myositis: report of a novel side-effect. <i>Clinical-scientific Notes. Internal Medicine Journal</i> , 2005, 35, 369-370.	0.5	11
146	Life-Threatening Interaction Between Complementary Medicines: Cyanide Toxicity Following Ingestion of Amygdalin and Vitamin C. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1566-1569.	0.9	79
147	Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experience. <i>ANZ Journal of Surgery</i> , 2004, 74, 951-956.	0.3	16
148	Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report. <i>BMC Cancer</i> , 2004, 4, 74.	1.1	51